JP2004529936A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004529936A5 JP2004529936A5 JP2002585441A JP2002585441A JP2004529936A5 JP 2004529936 A5 JP2004529936 A5 JP 2004529936A5 JP 2002585441 A JP2002585441 A JP 2002585441A JP 2002585441 A JP2002585441 A JP 2002585441A JP 2004529936 A5 JP2004529936 A5 JP 2004529936A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- schizophrenia
- dementia
- syndrome
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 201000000980 schizophrenia Diseases 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 206010057852 Nicotine dependence Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 208000025569 Tobacco Use disease Diseases 0.000 description 3
- 208000000323 Tourette Syndrome Diseases 0.000 description 3
- 208000016620 Tourette disease Diseases 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000006931 brain damage Effects 0.000 description 3
- 231100000874 brain damage Toxicity 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 231100000167 toxic agent Toxicity 0.000 description 3
- 208000000103 Anorexia Nervosa Diseases 0.000 description 2
- 208000032841 Bulimia Diseases 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10121215A DE10121215A1 (de) | 2001-04-30 | 2001-04-30 | Dihydro-imidazo[4,5-e]indol- und 7H-Pyrrolo[3,2-f]chinoxalin Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden |
| PCT/EP2002/003582 WO2002088143A2 (en) | 2001-04-30 | 2002-03-30 | Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004529936A JP2004529936A (ja) | 2004-09-30 |
| JP2004529936A5 true JP2004529936A5 (enExample) | 2009-06-04 |
| JP4593879B2 JP4593879B2 (ja) | 2010-12-08 |
Family
ID=7683301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002585441A Expired - Fee Related JP4593879B2 (ja) | 2001-04-30 | 2002-03-30 | ニコチン性アセチルコリンレセプターリガンドおよび／またはセロトニン作動性リガンドとしてのジヒドロイミダゾ［４，５−ｅ］インドールおよび７Ｈ−ピロロ［３，２−ｆ］キノキサリン誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7279496B2 (enExample) |
| EP (1) | EP1383774B1 (enExample) |
| JP (1) | JP4593879B2 (enExample) |
| AR (1) | AR033624A1 (enExample) |
| AT (1) | ATE394404T1 (enExample) |
| AU (1) | AU2002310904B2 (enExample) |
| CA (1) | CA2445834C (enExample) |
| CZ (1) | CZ20033195A3 (enExample) |
| DE (2) | DE10121215A1 (enExample) |
| ES (1) | ES2303857T3 (enExample) |
| HU (1) | HUP0304046A2 (enExample) |
| SK (1) | SK14472003A3 (enExample) |
| WO (1) | WO2002088143A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1656093A (zh) | 2002-05-30 | 2005-08-17 | 神经研究公司 | 3－取代的奎宁环及其用途 |
| US20050171079A1 (en) * | 2004-02-04 | 2005-08-04 | Schrimpf Michael R. | Amino-substituted tricyclic derivatives and methods of use |
| WO2007063418A2 (en) | 2005-04-13 | 2007-06-07 | Neuraxon, Inc. | Substituted indole compounds having nos inhibitory activity |
| US7897766B2 (en) * | 2005-09-23 | 2011-03-01 | Abbott Laboratories | Amino-aza-adamantane derivatives and methods of use |
| JP5350219B2 (ja) * | 2006-04-13 | 2013-11-27 | ニューラクソン，インコーポレーテッド | Ｎｏｓ阻害活性を有する１，５および３，６−置換インドール化合物 |
| EP2219449A4 (en) * | 2007-11-16 | 2010-10-27 | Univ Arizona State | METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING |
| CA2705833A1 (en) * | 2007-11-16 | 2009-05-22 | Subhash C. Annedi | 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity |
| BRPI0820632A2 (pt) * | 2007-11-16 | 2015-06-16 | Neuraxon Inc | Compostos de indol e métodos para tratamento de dor visceral |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4009565A1 (de) * | 1990-03-24 | 1991-09-26 | Merck Patent Gmbh | Indolderivate |
| WO1994009000A1 (en) | 1992-10-13 | 1994-04-28 | Warner-Lambert Company | Quinoxalinedione derivatives as eaa antagonists |
| JP3439215B2 (ja) * | 1993-05-13 | 2003-08-25 | ノイロサーチ アクティーゼルスカブ | Ａｍｐａ拮抗薬およびそれを用いての治療方法 |
| US5843945A (en) | 1993-05-13 | 1998-12-01 | Neurosearch A/S | AMPA antagonists and a method of treatment |
| US6548530B1 (en) * | 1995-10-03 | 2003-04-15 | The Scripps Research Institute | CBI analogs of CC-1065 and the duocarmycins |
| ATE266029T1 (de) * | 1998-02-26 | 2004-05-15 | Ortho Mcneil Pharm Inc | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung |
-
2001
- 2001-04-30 DE DE10121215A patent/DE10121215A1/de not_active Withdrawn
-
2002
- 2002-03-30 EP EP02735200A patent/EP1383774B1/en not_active Expired - Lifetime
- 2002-03-30 SK SK1447-2003A patent/SK14472003A3/sk unknown
- 2002-03-30 CZ CZ20033195A patent/CZ20033195A3/cs unknown
- 2002-03-30 AU AU2002310904A patent/AU2002310904B2/en not_active Ceased
- 2002-03-30 WO PCT/EP2002/003582 patent/WO2002088143A2/en not_active Ceased
- 2002-03-30 US US10/476,234 patent/US7279496B2/en not_active Expired - Fee Related
- 2002-03-30 HU HU0304046A patent/HUP0304046A2/hu unknown
- 2002-03-30 AT AT02735200T patent/ATE394404T1/de not_active IP Right Cessation
- 2002-03-30 ES ES02735200T patent/ES2303857T3/es not_active Expired - Lifetime
- 2002-03-30 CA CA2445834A patent/CA2445834C/en not_active Expired - Fee Related
- 2002-03-30 DE DE60226428T patent/DE60226428D1/de not_active Expired - Lifetime
- 2002-03-30 JP JP2002585441A patent/JP4593879B2/ja not_active Expired - Fee Related
- 2002-04-26 AR ARP020101529A patent/AR033624A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100513406C (zh) | 新的奎宁环衍生物及其用途 | |
| JP4198989B2 (ja) | セロトニン作動性薬 | |
| RU2018130727A (ru) | Органические соединения | |
| JP2005511613A (ja) | 疾患治療用アザビシクロ置換ヘテロアリール化合物 | |
| WO2008108517A3 (en) | Piperazinyl-propyl-pyrazole derivatives as dopamine d4 receptor antagonists, and pharmaceutical compositions containing the same | |
| TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| CN102512406A (zh) | 用于治疗认知障碍的α-氨基酰胺衍生物 | |
| FR2832713A1 (fr) | Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique | |
| AU2025267332A1 (en) | Psychotropic agents and uses thereof | |
| PL1678172T3 (pl) | Związki azabicykliczne do łagodzenia bólu oraz leczenia zaburzeń centralnego układu nerwowego | |
| JP2005523287A (ja) | 疾患治療用アザビシクロ化合物 | |
| MY140835A (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| JP2019534327A5 (enExample) | ||
| US7148353B2 (en) | Imidazo[1,2-a] pyridine anxiolytics | |
| JP2005537297A (ja) | アルファ−７ｎａｃｈｒ活性を有する１ｈ−ピラゾールおよび１ｈ−ピロール−アザビシクロ化合物 | |
| US8198296B2 (en) | Sub-type selective azabicycloalkane derivatives | |
| Tatsumi et al. | (R)-3 ‘-(3-Methylbenzo [b] thiophen-5-yl) spiro [1-azabicyclo [2, 2, 2] octane-3, 5 ‘-oxazolidin]-2 ‘-one, a Novel and Potent α7 Nicotinic Acetylcholine Receptor Partial Agonist Displays Cognitive Enhancing Properties | |
| JP2004529936A5 (enExample) | ||
| JP2006503062A5 (enExample) | ||
| BRPI0610028A2 (pt) | combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos | |
| JP6817073B2 (ja) | セロトニン受容体を標的にする化合物および方法 | |
| TW200635589A (en) | Therapeutic agents | |
| JP2007516292A5 (enExample) | ||
| JPWO2020132474A5 (enExample) | ||
| JP5528434B2 (ja) | ニューロンｎＡＣｈＲの無痛性脱感作剤およびその使用方法 |